These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 14719196)

  • 1. Efficacy and safety of leflunomide and predisposing factors for treatment response in patients with active rheumatoid arthritis: RELIEF 6-month data.
    Dougados M; Emery P; Lemmel EM; de la Serna R; Zerbini CA; Brin S; van Riel P
    J Rheumatol; 2003 Dec; 30(12):2572-9. PubMed ID: 14719196
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study.
    Kalden JR; Schattenkirchner M; Sörensen H; Emery P; Deighton C; Rozman B; Breedveld F
    Arthritis Rheum; 2003 Jun; 48(6):1513-20. PubMed ID: 12794818
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trial.
    Pincus T; Strand V; Koch G; Amara I; Crawford B; Wolfe F; Cohen S; Felson D
    Arthritis Rheum; 2003 Mar; 48(3):625-30. PubMed ID: 12632413
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis.
    Silverman E; Spiegel L; Hawkins D; Petty R; Goldsmith D; Schanberg L; Duffy C; Howard P; Strand V
    Arthritis Rheum; 2005 Feb; 52(2):554-62. PubMed ID: 15693001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis.
    Lee SS; Park YW; Park JJ; Kang YM; Nam EJ; Kim SI; Lee JH; Yoo WH; Lee SI
    Scand J Rheumatol; 2009; 38(1):11-4. PubMed ID: 19191187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial.
    Lambert CM; Sandhu S; Lochhead A; Hurst NP; McRorie E; Dhillon V
    Arthritis Rheum; 2004 Feb; 50(2):364-71. PubMed ID: 14872477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. When a DMARD fails, should patients switch to sulfasalazine or add sulfasalazine to continuing leflunomide?
    Dougados M; Emery P; Lemmel EM; Zerbini CA; Brin S; van Riel P
    Ann Rheum Dis; 2005 Jan; 64(1):44-51. PubMed ID: 15271770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis.
    Keystone E; Fleischmann R; Emery P; Furst DE; van Vollenhoven R; Bathon J; Dougados M; Baldassare A; Ferraccioli G; Chubick A; Udell J; Cravets MW; Agarwal S; Cooper S; Magrini F
    Arthritis Rheum; 2007 Dec; 56(12):3896-908. PubMed ID: 18050221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved functional ability in patients with rheumatoid arthritis--longterm treatment with leflunomide versus sulfasalazine. European Leflunomide Study Group.
    Kalden JR; Scott DL; Smolen JS; Schattenkirchner M; Rozman B; Williams BD; Kvien TK; Jones P; Williams RB; Oed C; Rosenburg R;
    J Rheumatol; 2001 Sep; 28(9):1983-91. PubMed ID: 11550964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: a 3-month, randomized, double-blind, placebo-controlled trial.
    Ogrendik M
    Clin Ther; 2009 Aug; 31(8):1754-64. PubMed ID: 19808134
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial.
    Poór G; Strand V;
    Rheumatology (Oxford); 2004 Jun; 43(6):744-9. PubMed ID: 15026583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks.
    Cohen SB; Emery P; Greenwald MW; Dougados M; Furie RA; Genovese MC; Keystone EC; Loveless JE; Burmester GR; Cravets MW; Hessey EW; Shaw T; Totoritis MC;
    Arthritis Rheum; 2006 Sep; 54(9):2793-806. PubMed ID: 16947627
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis.
    Weinblatt ME; Kremer JM; Coblyn JS; Maier AL; Helfgott SM; Morrell M; Byrne VM; Kaymakcian MV; Strand V
    Arthritis Rheum; 1999 Jul; 42(7):1322-8. PubMed ID: 10403258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.
    Cohen SB; Cheng TT; Chindalore V; Damjanov N; Burgos-Vargas R; Delora P; Zimany K; Travers H; Caulfield JP
    Arthritis Rheum; 2009 Feb; 60(2):335-44. PubMed ID: 19180516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Associations between the American College of Rheumatology pediatric response measures and the continuous measures of disease activity used in adult rheumatoid arthritis: a secondary analysis of clinical trial data from children with polyarticular-course juvenile idiopathic arthritis.
    Ringold S; Chon Y; Singer NG
    Arthritis Rheum; 2009 Dec; 60(12):3776-83. PubMed ID: 19950286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis.
    Saruhan-Direskeneli G; Inanc M; Fresko I; Akkoc N; Dalkilic E; Erken E; Karaaslan Y; Kinikli G; Oksel F; Pay S; Yucel E; Yentür SP; Duymaz-Tozkir J; Yilmaz V; Inanc N; Yazici H; Konice M; Direskeneli H
    Rheumatology (Oxford); 2007 Dec; 46(12):1842-4. PubMed ID: 18032542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adsorptive granulocyte/monocyte apheresis for the treatment of refractory rheumatoid arthritis: an open pilot multicentre trial.
    Sanmartí R; Marsal S; Valverde J; Casado E; Lafuente R; Kashiwagi N; Rodriguez-Cros JR; Erra A; Reina D; Gratacós J
    Rheumatology (Oxford); 2005 Sep; 44(9):1140-4. PubMed ID: 15927997
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction of the efficacy of methotrexate by the use of folic acid: post hoc analysis from two randomized controlled studies.
    Khanna D; Park GS; Paulus HE; Simpson KM; Elashoff D; Cohen SB; Emery P; Dorrier C; Furst DE
    Arthritis Rheum; 2005 Oct; 52(10):3030-8. PubMed ID: 16200612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
    Gibofsky A; Rodrigues J; Fiechtner J; Berger M; Pan S
    Clin Ther; 2007 Jun; 29(6):1071-85. PubMed ID: 17692722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial.
    Keystone EC; Schiff MH; Kremer JM; Kafka S; Lovy M; DeVries T; Burge DJ
    Arthritis Rheum; 2004 Feb; 50(2):353-63. PubMed ID: 14872476
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.